US 12,421,281 B2
Cyclosporine compositions and methods of use
Chris Murphy, Upton, MA (US); Ronald Farquhar, Boston, MA (US); and Roland E. Dolle, Eureka, MO (US)
Assigned to Bacainn Biotherapeutics, Ltd., George Town (KY)
Filed by Bacainn Biotherapeutics, Ltd., George Town (KY)
Filed on Aug. 19, 2022, as Appl. No. 17/891,351.
Application 17/891,351 is a continuation of application No. PCT/US2021/018999, filed on Feb. 22, 2021.
Claims priority of provisional application 62/981,750, filed on Feb. 26, 2020.
Prior Publication US 2023/0192771 A1, Jun. 22, 2023
Int. Cl. A61P 17/00 (2006.01); A61P 29/00 (2006.01); C07K 7/64 (2006.01)
CPC C07K 7/645 (2013.01) [A61P 17/00 (2018.01); A61P 29/00 (2018.01)] 18 Claims
 
1. A compound having the structure of Formula I,

OG Complex Work Unit Chemistry
a stereoisomer thereof, or a pharmaceutically acceptable salt of the foregoing,
wherein
L1 is a C1-6 alkylene group optionally substituted with one or more F;
L2 is absent or is a linker selected from O, NH, or a C1-12 alkylene or heteroalkylene group;
L3 is a C1-6 alkylene group;
L4 is a methylene or ethylene group; and
R is a polyethylene glycol (PEG) group.